ERBB2 and neoplasm: The 4-in-one CrossMab targeting EGFR, HER2, HER3 and VEGF 89 showed superior antitumor activity in different cancer models in vivo relative to combinations of BsAb, and they did so at lower antibody concentrations enabled by higher-avidity binding of tumor cells.